Structure Therapeutics, Inc. (GPCR)
42.38
+0.85
(+2.05%)
USD |
NASDAQ |
Jun 11, 11:41
Structure Therapeutics Debt to Equity Ratio : 0.004 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.004 |
| December 31, 2025 | 0.0043 |
| September 30, 2025 | 0.0092 |
| June 30, 2025 | 0.0099 |
| March 31, 2025 | 0.0092 |
| December 31, 2024 | 0.0045 |
| September 30, 2024 | 0.0049 |
| June 30, 2024 | 0.0051 |
| March 31, 2024 | 0.0119 |
| Date | Value |
|---|---|
| December 31, 2023 | 0.012 |
| September 30, 2023 | 0.02 |
| June 30, 2023 | 0.0003 |
| March 31, 2023 | 0.0007 |
| December 31, 2022 | 0.0031 |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 0.0061 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Eli Lilly & Co. | 1.390 |
| Novo Nordisk A/S | 0.7209 |
| Viking Therapeutics, Inc. | 0.00 |
| Pfizer Inc. | 0.7154 |
| Tarsus Pharmaceuticals, Inc. | 0.2541 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.508B |
| Total Liabilities (Quarterly) | 61.03M |
| Shareholders Equity (Quarterly) | 1.447B |
| Current Ratio | 26.16 |
| Net Debt Paydown Yield | -0.01% |